Therefore, our research findings, indicating that knockout of CHEK2 selectively weakens the relevant biological functions of HCC cells with TP53 mutations, may provide a potential target for TP53-mutant HCC cells. This evidence concerns the gene CHEK2 and hepatocellular carcinoma.